$VSTM

Calkins Daniel sold $17K of VSTM

Calkins Daniel (Chief Financial Officer) sold 4,089 shares of Verastem, Inc. (VSTM) at an average of $4.18 ($4.13–$4.18) across 2 trades on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Calkins Daniel
Published Jun 24, 2026, 8:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VSTM
Neutral
medium confidence
Mentioned
$VSTM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VSTMNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider activity but does not include new operational, financial, or regulatory developments.

02

Market read

Traders may monitor whether this is part of a broader selling cadence, but the single, small 10b5-1 sale is unlikely to drive a major repricing.

03

What to watch

The sale size is small and explicitly pre-arranged; without additional context (e.g., repeated sales pattern, option exercises), the signal is limited.

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-24 after-hours; reflects 2026-06-22 sale execution.

Background

This is an SEC Form 4 insider transaction for Verastem, Inc. (VSTM) by CFO Daniel Calkins.

Company-level read

Ticker impact

$VSTMNeutralMedium confidence
Context

Verastem CFO Daniel Calkins sold $17.1K of VSTM shares in an open-market transaction under a 10b5-1 plan, disclosed via Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a routine Form 4 insider sale with a stated 10b5-1 plan and modest dollar value relative to typical market moves.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with internal views on near-term risk; traders may still fade/trim on the headline if liquidity is thin.

Key entities

  • Verastem, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Daniel Calkins

    CFO who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVCRLowAI 8/10

Novocure partners with Verastem on pancreatic cancer trial

Novocure (NVCR) and Verastem Oncology (VSTM) partner to test Tumor Treating Fields therapy with VS-7375 for pancreatic cancer. Trial to start in 2027, focusing on safety and tolerability in 25 patients. Novocure will fund and manage the trial, while Verastem supplies the drug. The treatment aims to combine chemotherapy, VS-7375, and Tumor Treating Fields. Pancreatic cancer has a low survival rate and limited treatment options.

$NVCRLowAI 8/10

A planned trial will test electric-field therapy with chemotherapy and an experimental drug.

Novocure (NVCR) and Verastem Oncology plan a clinical trial to evaluate Tumor Treating Fields (TTFields) therapy with chemotherapy and Verastem’s experimental drug VS-7375 for locally advanced pancreatic cancer. The trial, expected to start in 2027, will assess safety and preliminary efficacy in about 25 patients. Novocure will manage and fund the trial, while Verastem will supply the drug. Both companies believe the combination could offer a new treatment approach for this challenging cancer.

$VSTMHighAI 8/10

Wainwright reiterates Verastem stock rating on China trial data

H.C. Wainwright reiterated a Buy rating and $18.00 price target for Verastem (VSTM) after positive clinical trial data from China. The stock rose 10% last week to $9.23, up 46% in six months. GenFleet's data showed promising results for GFH375, the same molecule as Verastem's VS-7375, in colorectal and pancreatic cancer trials. Analysts maintain a strong buy consensus with targets ranging from $12 to $24.